X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IG-002 addresses all forms of ABCA4-related retinopathies, a subretinal administration of a DNA payload encoding the human ABCA4 gene resulted in durable (12-month) expression of human ABCA4 protein in adult porcine retinas.
Lead Product(s): IG-002
Therapeutic Area: Genetic Disease Product Name: IG-002
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Details:
Intergalactic’s non-viral gene therapy deploys two proprietary technologies: 1) C3DNA, covalently closed and circular DNA which relies on a cellfree manufacturing process; and 2) COMET, a clinically advanced, pulsed electric field focal gene therapy delivery system.
Lead Product(s): Non-viral Based Gene Therapy
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ATPGroup
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 07, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
